Sarbajit Mukherjee

Medical Oncology

Specializing In:

Esophageal Cancer Gastric Cancer Neuroendocrine Tumors Colon Cancer

Special Interests:

Use of immune checkpoint inhibitors in solid tumors

About Sarbajit Mukherjee


I am a gastrointestinal (GI) medical oncologist with a research interest in gastroesophageal cancers and cancer immunotherapy. I completed my clinical training in adult hematology-oncology at the University of Oklahoma, USA, and research training at Oklahoma Medical Research Foundation, where I gained extensive, hands-on lab experience. I also earned a Master's degree in Clinical and Translational science during my fellowship. Besides, I attended several workshops, including the prestigious Vail workshop, to hone my clinical research skills. I became board certified in both Hematology and Medical Oncology in 2018.

I have had the opportunity to serve the American Society of Clinical Oncology (ASCO) as a volunteer. I have been a member of the Trainee Council Working Group, Clinical Practice Guidelines Committee, and the Professional Development Committee at ASCO. I have also served on multiple guidelines panel for ASCO. I am a panel member at the National Comprehensive Cancer Network(NCCN). I also serve as a member of the board of directors at the Esophageal Cancer Action Network.

I have been fortunate to receive many awards, including memberships in Alpha Omega Alpha medical honor society and Gold Humanism Honor Society. I also received a merit award from ASCO.

My current work focuses on novel clinical trials in GI malignancies using circulating tumor DNA as a correlative marker. I have conducted multiple investigator-initiated clinical trials, including an NCI (National Cancer Institute) funded phase 2 trial, as a principal investigator. Besides, I am also interested in understanding the impact of obesity on immune dysfunction in cancer. I received peer-reviewed grants from NCCN and North American Neuroendocrine Tumor Society (NANETS). My work has been presented at many national/international conferences and published in high impact journals like Nature Medicine. I have peer-reviewed scientific articles for several prestigious journals like Clinical Cancer Research.

For me, caring for a cancer patient is more than treating a disease; it's a healing process that involves both the patient's body and mind. I would like to see myself as a successful clinical and translational researcher and a compassionate physician, and a thought leader in the field of GI cancers.


Roswell Park Comprehensive Cancer

  • Assistant Professor of Oncology
  • Department of Medicine
  • Member: Tumor Immunology and Immunotherapy Program (TII)

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

  • Clinical Assistant Professor


Education and Training:

  • 2010 - MD - Nilratan Sircar Medical College, West Bengal University of Health Sciences, India
  • 2018 - MS - Master of Science in Clinical and Translational Science, University of Oklahoma, Oklahoma City, OK


  • 2012-2015 - Saint Joseph Hospital, Chicago, IL


  • 2015-2018 - University of Oklahoma Health Sciences Center, Oklahoma City, OK

Board Certification:

  • 2018 - Medical Oncology - American Board of Internal Medicine
  • 2018 - Hematology - American Board of Internal Medicine
  • 2015 - Internal Medicine - American Board of Internal Medicine

Professional Memberships:

  • Society for Immunotherapy of Cancer
  • American Association for Cancer Research
  • American College of Gastroenterology
  • North American Neuroendocrine Tumor Society
  • European Society of Medical Oncology
  • American Society of Clinical Oncology

Professional Experience:

  • 2021-present - Quality Subcommittee, Society for Immunotherapy of Cancer (SITC)
  • 2021-present - Guidelines committee, International Society of the Diseases of the Esophagus
  • 2018-present - Member, Occult Primary Panel, NCCN
  • 2018-present - Board of Directors, Esophageal Cancer Action Network
  • 2017-2018 - Chief fellow, Hematology-Oncology, University of Oklahoma
  • 2017-2018 - Clinical Practice Guidelines Committee, ASCO
  • 2016-2018 - Professional Development Committee, ASCO

Honors & Awards:

  • Clinical Investigator Scholarship Award, North American Neuroendocrine Tumor Society
  • ASCO/AACR Methods in Clinical Cancer Workshop, Vail, CO
  • James N. George award for the outstanding fellow in hematology-oncology, University of Oklahoma
  • Gold Humanism Honor Society
  • Conquer Cancer Foundation Merit Award, ASCO
  • Alpha Omega Alpha (AOA) Honor Medical Society
  • Early Career Reviewer, Developmental Therapeutics (DT), Center for Scientific Review, National Institutes of Health

Clinical Trials

Featured on Cancer Talk


Full Publications list on PubMed

Mukherjee S, Fountzilas C, Boland PM, Gosain R, Attwood K, Tan W, Khushalani N, Iyer R. Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Target Oncol. 2019 Dec 4. PubMed PMID: 31802410.

Malhotra U*, Mukherjee S*, Fountzilas C, Boland P, Miller A, Patnaik S, Attwood K, Yendamuri S, Adjei A, Kannisto E, Opyrchal M, Bushunow P, Loud P, Iyer R, Khushalani NI. Pralatrexate in combination with oxaliplatin in advanced esophago-gastric cancer: a phase II trial with predictive molecular correlates. Mol Cancer Ther. 2020 Jan;19(1):304-311.PubMed PMID: 31575653. *co-first author

Gosain R, Ball S, Rana N, Groman A, Gage-Bouchard E, Dasari A, Mukherjee S. Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study. Cancer. 2019 Nov 12. PubMed PMID: 31714595.

Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, Grossenbacher SK, Withers SS, Rebhun RB, Hartigan-O'Connor DJ, Méndez-Lagares G, Tarantal AF, Isseroff RR, Griffith TS, Schalper KA, Merleev A, Saha A, Maverakis E, Kelly K, Aljumaily R, Ibrahimi S, Mukherjee S, Machiorlatti M, Vesely SK, Longo DL, Blazar BR, Canter RJ, Murphy WJ, Monjazeb AM. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019 Jan; 25(1):141-151. PubMed PMID: 30420753.

Mukherjee S, Ibrahimi S, Khalid B, Roman D, Zhao D, Aljumaily R. Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study. J Oncol Pharm Pract. 2018 Jan 1:1078155218771152. PubMed PMID: 29690815.